How Ipamorelin Works in the Research: GHS-R1a, GH Pulse & the Gut
In plain English
What does ipamorelin peptide do? In one breath: it flips a single receptor switch that has two effects. Ipamorelin is a tiny five-amino-acid peptide. The switch it flips is the ghrelin receptor (called GHS-R1a) — the same one your body's hunger hormone uses. That receptor lives in two helpful spots. In the pituitary, the small gland under the brain that controls hormones, flipping it releases a short burst of growth hormone — the body's main signal for building and repairing tissue. In the nerves around your gut, flipping it speeds the muscles that push food along. The clever part is what ipamorelin does not do: unlike older peptides in its family, it leaves the stress hormone cortisol and the milk hormone prolactin mostly alone, even at high doses. That "clean" pulse is its whole selling point in the research. Below, each piece is explained and tied to the study that measured it.
What is ipamorelin peptide
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from GHRP-1 by removing the central Ala-Trp dipeptide. The non-natural Aib (alpha-aminoisobutyric acid) at position 1, plus the D-form amino acids, make it resistant to the enzymes that normally chew up peptides. Functionally it is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). Its founding 1998 paper established the defining behavior: potent GH release (swine ED50 2.3 nmol/kg) with no rise in ACTH or cortisol even at doses 200-fold above the GH ED50 [1]. That selectivity is what separates it from GHRP-6 and GHRP-2.
The two-pathway mechanism, step by step
Step one is binding. Ipamorelin docks onto GHS-R1a on pituitary somatotrophs and triggers the Gq/PLC pathway, raising intracellular calcium and releasing a pulse of growth hormone [1]. Step two is downstream: that GH pulse can drive hepatic IGF-1 in sustained protocols, though short rodent studies did not always show an IGF-1 rise [4]. Step three is the gut arm: the same receptor on enteric and vagal neurons drives a prokinetic (gut-moving) effect, demonstrated as accelerated gastric emptying in a rat ileus model via ghrelin-receptor/cholinergic activation [8]. There is even a peripheral feedback loop — GHRPs partly act by triggering endogenous ghrelin release from the gastric mucosa, since gastric resection cut GHRP-6-induced GH release by 60-70% [11]. One receptor, three measurable consequences: a GH pulse, a downstream IGF-1 signal, and a gut-motility push.
What is cjc 1295 ipamorelin
CJC-1295 ipamorelin refers to the popular pairing of two different growth-hormone-raising peptides. CJC-1295 is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. They are combined because they raise GH through separate, complementary pathways: the GHRH arm and the ghrelin arm [1]. The theory is that hitting both doors at once yields a larger GH pulse than either alone. It is important to be precise: this page describes pure ipamorelin pharmacology; the combination itself has no controlled human outcome trial.
Ipamorelin cjc-1295
The ipamorelin cjc-1295 combination is built on a genuine pharmacological rationale — two non-overlapping mechanisms converging on growth-hormone release — but the evidence base is single-agent, not combination. Ipamorelin contributes the selective, cortisol-sparing GH pulse [1]; the GHRH analog contributes a longer-acting GHRH-receptor signal. What does not exist is a trial of the combination for any endpoint, which is why the popular stack rests on extrapolation from each compound's separate pharmacology rather than on demonstrated combined efficacy.
Does cjc-1295 ipamorelin work
For acutely raising growth hormone, the single-agent pharmacology supports a GH pulse — ipamorelin's swine GH ED50 is 2.3 nmol/kg with a clean selectivity profile [1]. Whether the cjc-1295 ipamorelin combination "works" for the outcomes people actually want — fat loss, muscle, anti-aging — is unproven: no controlled human trial has tested it for any clinical endpoint, and ipamorelin's own lone human efficacy trial missed its primary endpoint [3]. The honest position is that the mechanism is well established while human outcome efficacy is not.
Ipamorelin vs sermorelin
Ipamorelin and sermorelin raise growth hormone through different receptors. Sermorelin is a GHRH analog (the first 29 amino acids of GHRH) that acts on the GHRH receptor; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. Because their mechanisms are complementary rather than redundant, the two are sometimes discussed together rather than as substitutes [1]. A practical difference in the literature: ipamorelin's defining trait is selectivity — a GH pulse without cortisol or prolactin elevation [1] — whereas GHRH analogs work upstream at the GHRH receptor. Neither is an approved drug for the physique uses they are marketed for.
Ipamorelin vs tesamorelin
Tesamorelin is a stabilized GHRH analog (GHRH 1-44 analog) that is FDA-approved specifically for HIV-associated lipodystrophy — a narrow, approved indication. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist that is not approved for anything. So the contrast is twofold: different mechanism (GHRH receptor versus ghrelin receptor) and very different regulatory standing. Tesamorelin has human trial data behind a specific approved use; ipamorelin's human record is a single failed Phase 2 trial [3] and a PK/PD study [2]. They are not interchangeable, and conflating ipamorelin's evidence with an approved GHRH analog's overstates ipamorelin's standing.